|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 3 (August 1), 1998:
pp. 990-995
Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis
in B Chronic Lymphocytic Leukemia Cells
Maria Fiammetta Romano,
Annalisa Lamberti,
Pierfrancesco Tassone,
Fiorella Alfinito,
Silvia Costantini,
Federico Chiurazzi,
Thierry Defrance,
Patrizio Bonelli,
Franca Tuccillo,
Maria Caterina Turco, and
Salvatore Venuta
From the Dipartimento di Biochimica e Biotecnologie Mediche,
Università Federico II, Napoli, Italia; Dipartimento di Oncologia
Sperimentale, Istituto Nazionale Tumori Napoli, Italia; Dipartimento di
Medicina Sperimentale e Clinica, Università of Reggio Calabria,
Italia; DACM area of Haematology, Università Federico II, Napoli,
Italia; and INSERM, Lyon, France.
We analyzed the effect of CD40 triggering on the
fludarabine-induced apoptosis of B chronic lymphocytic leukemia (B-CLL)
cells. Peripheral blood samples obtained from 15 patients were
incubated with fludarabine in the absence or the presence of the
anti-CD40 monoclonal antibody (MoAb) G28-5. In 12 patients a
significant proportion of apoptotic cells, ranging from 22% to 38%
(mean ± SE: 28.5 ± 1.6), were detected after 3 days of culture.
In 9 of these samples, the addition of G28-5 reduced apoptosis by at
least 30.1% and by 57.1% ± 7.8% on average
(P = .0077). Because the CD40 antigen activates NF- B/Rel
transcription factors in B cells, and NF-B/Rel complexes can inhibit
cell apoptosis, we investigated whether the antiapoptotic effect of
G28-5, in our system, could be related to modulation of NF-B/Rel
activity. As expected, B-CLL cells displayed significant levels of
nuclear NF-B/Rel activity; p50, RelA, and c-Rel components of the
NF-B/Rel protein family were identified in these complexes. After
exposure to fludarabine, NF-B/Rel complexes were decreased in the
nuclei. The addition of G28-5 upregulated the NF-B/Rel levels. To
determine the involvement of NF-B/Rel activity in the
G28-5-mediated inhibition of apoptosis, we blocked the transcription
factor with a decoy oligonucleotide, corresponding to the NF-B/Rel
consensus sequence. Cells incubated with the anti-CD40 MoAb in the
presence of the decoy oligonucleotide but not a control
oligonucleotide displayed a complete impairment of the
G28-5 antiapoptotic effect, indicating that NF-B/Rel activity was
required for the inhibition of apoptosis. These results suggest that
CD40 triggering in vivo could counteract the apoptotic effect of
fludarabine on B-CLL cells and that its neutralization, or the use of
NF-B/Rel inhibitors, could improve the therapeutic effect of
fludarabine.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Luqman, S. Klabunde, K. Lin, G. V. Georgakis, A. Cherukuri, J. Holash, C. Goldbeck, X. Xu, E. E. Kadel III, S. H. Lee, et al.
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Blood,
August 1, 2008;
112(3):
711 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Secchiero, E. Melloni, M. Tiribelli, A. Gonelli, and G. Zauli
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells
J. Leukoc. Biol.,
February 1, 2008;
83(2):
434 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Kater, M. H. J. van Oers, and T. J. Kipps
Cellular immune therapy for chronic lymphocytic leukemia
Blood,
October 15, 2007;
110(8):
2811 - 2818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Mineva, T. L. Rothstein, J. A. Meyers, A. Lerner, and G. E. Sonenshein
CD40 Ligand-mediated Activation of the de Novo RelB NF-{kappa}B Synthesis Pathway in Transformed B Cells Promotes Rescue from Apoptosis
J. Biol. Chem.,
June 15, 2007;
282(24):
17475 - 17485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Smit, D. Y.H. Hallaert, R. Spijker, B. de Goeij, A. Jaspers, A. P. Kater, M. H.J. van Oers, C. J.M. van Noesel, and E. Eldering
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity
Blood,
February 15, 2007;
109(4):
1660 - 1668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dicker, A. P. Kater, C. E. Prada, T. Fukuda, J. E. Castro, G. Sun, J. Y. Wang, and T. J. Kipps
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53
Blood,
November 15, 2006;
108(10):
3450 - 3457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Giordano, R. Avellino, P. Ferraro, S. Romano, N. Corcione, and M. F. Romano
Rapamycin antagonizes NF-{kappa}B nuclear translocation activated by TNF-{alpha} in primary vascular smooth muscle cells and enhances apoptosis
Am J Physiol Heart Circ Physiol,
June 1, 2006;
290(6):
H2459 - H2465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Petlickovski, L. Laurenti, X. Li, S. Marietti, P. Chiusolo, S. Sica, G. Leone, and D. G. Efremov
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells
Blood,
June 15, 2005;
105(12):
4820 - 4827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dicker, A. P. Kater, T. Fukuda, and T. J. Kipps
Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells
Blood,
April 15, 2005;
105(8):
3193 - 3198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Bergwelt-Baildon, B. Maecker, J. Schultze, and J. G. Gribben
CD40 activation: potential for specific immunotherapy in B-CLL
Ann. Onc.,
June 1, 2004;
15(6):
853 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol.,
September 15, 2003;
21(18):
3526 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol.,
September 1, 2003;
74(3):
311 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Granziero, P. Circosta, C. Scielzo, E. Frisaldi, S. Stella, M. Geuna, S. Giordano, P. Ghia, and F. Caligaris-Cappio
CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes
Blood,
March 1, 2003;
101(5):
1962 - 1969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Munzert, D. Kirchner, H. Stobbe, L. Bergmann, R. M. Schmid, H. Dohner, and H. Heimpel
Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis
Blood,
November 15, 2002;
100(10):
3749 - 3756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bernal, R. D. Pastore, Z. Asgary, S. A. Keller, E. Cesarman, H.-C. Liou, and E. J. Schattner
Survival of leukemic B cells promoted by engagement of the antigen receptor
Blood,
November 15, 2001;
98(10):
3050 - 3057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Chu, W. G. Wierda, and T. J. Kipps
CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes
Blood,
June 15, 2000;
95(12):
3853 - 3858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Furman, Z. Asgary, J. O. Mascarenhas, H.-C. Liou2, and E. J. Schattner
Modulation of NF-{kappa}B Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells
J. Immunol.,
February 15, 2000;
164(4):
2200 - 2206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Romano, A. Lamberti, R. Bisogni, C. Garbi, A. M. Pagnano, P. Auletta, P. Tassone, M. C. Turco, and S. Venuta
Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-kappa B/Rel Transcription Factors
Blood,
December 15, 1999;
94(12):
4060 - 4066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
